<DOC>
	<DOC>NCT00393835</DOC>
	<brief_summary>To evaluate the clinical efficacy and safety in patients with Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis receiving a dose of 2 g of azithromycin in the SR formulation.</brief_summary>
	<brief_title>A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Tonsillitis</mesh_term>
	<criteria>Patients who were diagnosed Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>